Comparing two chemo combinations for older adults with AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if adding a second drug (venetoclax) to a standard chemotherapy (azacitidine) works better than the standard alone for adults aged 60 to 75 with newly diagnosed acute myeloid leukemia (AML).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 75 years old.
- You have been diagnosed with a type of AML (not APL) that is not considered low-risk.
- You have not had prior chemotherapy for AML (except hydroxyurea) or certain other prior treatments.
- Your organs (kidneys, liver, lungs) are working reasonably well.
- You are willing to use effective contraception if you or your partner can become pregnant.
- You do not have serious heart, liver, or kidney disease, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs, medium-dose cytarabine and venetoclax, as a follow-up treatment (consolidation) to keep leukemia from coming back. It is for older adults with intermediate or high-risk acute myeloid leukemia who have already achieved remission after their first round of therapy.
This trial compares a new combination of drugs (venetoclax, azacitidine, and liposomal mitoxantrone) against a standard chemotherapy regimen (idarubicin and cytarabine) for people with newly diagnosed acute myeloid leukemia (AML). It tests whether the new combination works better and is safe.
This trial tests two different intensities of venetoclax (a targeted pill) combined with standard chemotherapy for people newly diagnosed with acute myeloid leukemia (AML). The goal is to find out which dose works better and is safer.
This clinical trial tests a combination of three drugs: a liposomal form of mitoxantrone (a type of chemotherapy), cytarabine (another chemo drug), and venetoclax (a targeted therapy). The goal is to see if this combination is safe and works well for older adults (ages 60-70) who have just been diagnosed with AML and cannot have standard intensive chemotherapy.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial compares two different combinations of chemotherapy drugs for older adults (ages 55-75) with newly diagnosed acute myeloid leukemia (AML) who are otherwise healthy enough to tolerate intensive treatment. The goal is to see which combination is more effective and has fewer side effects.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.